Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb

PHASE2CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

October 11, 2013

Primary Completion Date

October 31, 2016

Study Completion Date

August 31, 2021

Conditions
Lymphoma
Interventions
DRUG

RCOMP

Day 1: Rituximab 375 mg/m2; Myocet® 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles

DRUG

RCHOP

Day 1: Rituximab 375 mg/m2; Doxorubicin 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles

Trial Locations (14)

28007

Hospital General Universitario Gregorio Marañón, Madrid

28031

Hospital Universitario Infanta Leonor, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

28922

Hospital Fundación de Alcorcón, Alcorcón

30120

Hospital Clínico Universitario Virgen de la Arrixaca, Murcia

33203

Hospital de Cabueñes, Gijón

37007

Hospital Universitario de Salamanca, Salamanca

39008

Hospital Universitario Marqués de Valdecilla, Santander

47005

Hospital Clínico Universitario de Valladolid, Valladolid

50009

Hospital Clínico Universitario Lozano Blesa, Zaragoza

Unknown

Hospital Universitario de Alava, Vitoria-Gasteiz

08916

Hospital Universitari Germans Trias i Pujol, Badalona

08908

ICO- Hospital Duran i Reynals, L'Hospitalet de Llobregat

08003

Hospital del Mar, Barcelona

All Listed Sponsors
lead

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

OTHER

NCT02012088 - Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb | Biotech Hunter | Biotech Hunter